⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 26, 2024World Journal of GastroenterologyOpen Access

Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus

Hongxiao Wu Xiaoyan Ding Yawen Xu Minghua Yu Xiao-Mi Li Na Deng Jinglong Chen

View Full Paper

Ask AI

Bookmark

Share

Abstract

Hepatocellular carcinoma (HCC) patients complicated with portal vein tumor thrombus (PVTT) exhibit poor prognoses and treatment responses.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wu et al. (2024) studied this question.

synapsesocial.com/papers/68e777b3b6db6435876ece14 https://doi.org/10.3748/wjg.v30.i8.843

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study2024 · 12 citations
2Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma2024 · 13 citations
3Effectiveness and safety of vascular intervention plus lenvatinib versus vascular intervention alone for hepatocellular carcinoma patients with portal vein tumor thrombus: a retrospective comparative study2024 · 1 citations
4Immunotherapy in Hepatocellular Carcinoma with Portal Vein Tumour Thrombosis: From Poor Prognosis to Curative-Intent StrategiesNarrative Review · 2026 · 1 citations
5Liver resection <i>versus</i> transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombusCohort Study · 2025